This article was originally published in The Gray Sheet
Executive SummaryComments are due within 30 days of the March 1 publication in the Federal Register of the Medical Devices Draft Guidance for Clinical Laboratory Improvement Amendments of 1988 Criteria for Waiver. The guidance includes an alternate path to waiver based on user comparability criteria, but also retains methods laid out in the 1995 proposed rule (1"The Gray Sheet" Jan. 29, 2001, p. 3)
You may also be interested in...
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.